Tobias Gabriel

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

Yan Lou, Xiaochun Han, A. Kuglstatter et al. · Journal of Medicinal Chemistry · 2014 · 106 citations

Pharmaceutical Science, Tyrosine Kinase, Immunology +18

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Ying Huang, Jeff Zhang, Zhengtian Yu et al. · Journal of Medicinal Chemistry · 2017 · 100 citations · Full text

Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

David Goldstein, Michael Soth, Tobias Gabriel et al. · Journal of Medicinal Chemistry · 2011 · 74 citations · Full text

Pharmacotherapy, New Series, System Pharmacology +21

The chromium—Reformatsky reaction: Asymmetric synthesis of the aldol fragment of the cytotoxic epothilons from 3-(2-bromoacyl)-2-oxazolidinones

Tobias Gabriel, Ludger A. Wessjohann · Tetrahedron Letters · 1997 · 64 citations

Aldol Fragment, Biochemistry, Asymmetric Synthesis +4